JP2002507223A - 脂質代謝異常によりもたらされる疾患の治療のための、アルカノイルl−カルニチンをスタチンと組み合わせて含む医薬組成物 - Google Patents
脂質代謝異常によりもたらされる疾患の治療のための、アルカノイルl−カルニチンをスタチンと組み合わせて含む医薬組成物Info
- Publication number
- JP2002507223A JP2002507223A JP50684499A JP50684499A JP2002507223A JP 2002507223 A JP2002507223 A JP 2002507223A JP 50684499 A JP50684499 A JP 50684499A JP 50684499 A JP50684499 A JP 50684499A JP 2002507223 A JP2002507223 A JP 2002507223A
- Authority
- JP
- Japan
- Prior art keywords
- carnitine
- alkanoyl
- composition
- statin
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT97A000390 | 1997-07-01 | ||
IT97RM000390A IT1293067B1 (it) | 1997-07-01 | 1997-07-01 | Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico |
PCT/IT1998/000163 WO1999001126A1 (en) | 1997-07-01 | 1998-06-18 | Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002507223A true JP2002507223A (ja) | 2002-03-05 |
Family
ID=11405149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50684499A Ceased JP2002507223A (ja) | 1997-07-01 | 1998-06-18 | 脂質代謝異常によりもたらされる疾患の治療のための、アルカノイルl−カルニチンをスタチンと組み合わせて含む医薬組成物 |
Country Status (10)
Country | Link |
---|---|
US (2) | US6180680B1 (xx) |
EP (2) | EP0983066A1 (xx) |
JP (1) | JP2002507223A (xx) |
KR (1) | KR100539066B1 (xx) |
AU (1) | AU726822B2 (xx) |
CA (1) | CA2295748A1 (xx) |
IL (1) | IL133492A (xx) |
IT (1) | IT1293067B1 (xx) |
NZ (1) | NZ501844A (xx) |
WO (1) | WO1999001126A1 (xx) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010519333A (ja) * | 2007-02-27 | 2010-06-03 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | 2型糖尿病の処置に有用な組成物 |
JP2011513246A (ja) * | 2008-02-29 | 2011-04-28 | バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー. | 医薬組成物 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6245800B1 (en) * | 1999-06-08 | 2001-06-12 | Sigma-Tau | Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine |
WO2000074675A1 (en) * | 1999-06-08 | 2000-12-14 | Sigma-Tau Industrie Farmaceutiche S.P.A. | Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines |
DK1064943T3 (da) * | 1999-06-30 | 2005-06-06 | Sigma Tau Ind Farmaceuti | Kombination med antilipemisk aktivitet, der i det væsentlige er fri for toksiske virkninger og bivirkninger som fölge af antilipemsike lægemidler |
US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
ITRM20040307A1 (it) | 2004-06-23 | 2004-09-23 | Sigma Tau Ind Farmaceuti | Confezione per almeno due prodotti differenti da vendere e utilizzare insieme. |
EP2136798B1 (en) * | 2007-03-21 | 2015-07-29 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance |
CA3073802A1 (en) | 2017-08-23 | 2019-02-28 | Gavish-Galilee Bio Applications Ltd. | Compositions and methods for treating atherosclerotic cardiovascular disease |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2903579A1 (de) * | 1978-02-03 | 1979-08-09 | Sigma Tau Ind Farmaceuti | Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel |
-
1997
- 1997-07-01 IT IT97RM000390A patent/IT1293067B1/it active IP Right Grant
-
1998
- 1998-06-18 AU AU79310/98A patent/AU726822B2/en not_active Ceased
- 1998-06-18 JP JP50684499A patent/JP2002507223A/ja not_active Ceased
- 1998-06-18 CA CA002295748A patent/CA2295748A1/en not_active Abandoned
- 1998-06-18 WO PCT/IT1998/000163 patent/WO1999001126A1/en active IP Right Grant
- 1998-06-18 IL IL13349298A patent/IL133492A/en not_active IP Right Cessation
- 1998-06-18 KR KR10-1999-7012633A patent/KR100539066B1/ko not_active IP Right Cessation
- 1998-06-18 US US09/446,806 patent/US6180680B1/en not_active Expired - Fee Related
- 1998-06-18 EP EP98929631A patent/EP0983066A1/en not_active Ceased
- 1998-06-18 NZ NZ501844A patent/NZ501844A/en not_active IP Right Cessation
- 1998-06-18 EP EP05105620A patent/EP1623708A3/en not_active Withdrawn
-
2004
- 2004-08-30 US US10/928,156 patent/US20050026846A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010519333A (ja) * | 2007-02-27 | 2010-06-03 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | 2型糖尿病の処置に有用な組成物 |
JP2014040442A (ja) * | 2007-02-27 | 2014-03-06 | Sigma Tau Ind Farmaceut Riunite Spa | 2型糖尿病の処置に有用な組成物 |
JP2011513246A (ja) * | 2008-02-29 | 2011-04-28 | バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー. | 医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
IT1293067B1 (it) | 1999-02-11 |
US6180680B1 (en) | 2001-01-30 |
KR20010014439A (ko) | 2001-02-26 |
CA2295748A1 (en) | 1999-01-14 |
US20050026846A1 (en) | 2005-02-03 |
ITRM970390A1 (it) | 1999-01-01 |
ITRM970390A0 (xx) | 1997-07-01 |
AU7931098A (en) | 1999-01-25 |
IL133492A0 (en) | 2001-04-30 |
AU726822B2 (en) | 2000-11-23 |
EP1623708A3 (en) | 2006-02-15 |
EP0983066A1 (en) | 2000-03-08 |
EP1623708A2 (en) | 2006-02-08 |
IL133492A (en) | 2004-07-25 |
WO1999001126A1 (en) | 1999-01-14 |
KR100539066B1 (ko) | 2005-12-26 |
NZ501844A (en) | 2001-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS63203621A (ja) | 高脂血症及び動脈硬化症の予防・治療薬 | |
JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
CN113784717A (zh) | 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药 | |
JP2002507223A (ja) | 脂質代謝異常によりもたらされる疾患の治療のための、アルカノイルl−カルニチンをスタチンと組み合わせて含む医薬組成物 | |
US8053472B2 (en) | Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus | |
JP2001518481A (ja) | 経口投与のためのセロトニン含有製剤及びその使用方法 | |
US6245800B1 (en) | Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine | |
EP1569635B1 (en) | Use of carnitines for the prevention and/or treatment of disorders caused by the andropause | |
EP1663174A1 (en) | Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent | |
US8003652B2 (en) | Use of acetyl L-carnitine in combination with propionyl L-carnitine and Sildenafil for the treatment of erectile dysfunction | |
KR100725263B1 (ko) | HMG-CoA 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제 | |
US7776913B2 (en) | Carnitines for treating or preventing disorders caused by andropause | |
CN108371712B (zh) | 咖啡因与PPARγ激动剂联合制备AD药物中的用途 | |
CN110585182A (zh) | 双硫仑在制备治疗和预防高血脂药物或动脉粥样硬化药物中的用途 | |
WO2008015763A1 (fr) | Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire | |
MXPA99011665A (en) | Pharmaceutical compositions comprising alkanoyl l-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism | |
JP2022540664A (ja) | 石灰化減少に用いる経口ピロリン酸二ナトリウム | |
EP1064943B1 (en) | Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs | |
JP2003535125A (ja) | カルボキシアルキルエーテル−acat阻害剤の組合せ | |
JP2002504934A (ja) | ケタンセリンとl−カルニチン又はアルカノイルl−カルニチンを含むcrpsの治療のための組成物 | |
JPH1129476A (ja) | 麻薬依存抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050105 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080819 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090106 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090310 |